Exai Bio Presents Data Demonstrating that its Novel RNA-based Liquid Biopsy Platform has Potential for Early Detection and Monitoring of Colorectal Cancer

PALO ALTO, Calif.–(BUSINESS WIRE)– #innovation–Exai Bio, a next-generation liquid biopsy company, and researchers at UCSF are presenting data from a new study in a poster entitled “Serum-based colorectal cancer detection using orphan noncoding RNAs” at the 2022 European Society of Medical Oncology (ESMO) meeting. This case-control study of 191 subjects…